Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeligekimab for mild-to-moderate psoriasis (single-arm, Phase 4, China)
ChiCTR2600123675Phase 4Recruiting
- Sponsor
- Shandong First Medical University Affiliated Dermatology Hospital
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of xeligekimab in psoriasis and plaque psoriasis, sponsored by Shandong First Medical University Affiliated Dermatology Hospital. Primary endpoint: 12-week PASI 90 response rate. Started Apr 2026; status: recruiting.
02
Drugs
xeligekimab
03
Conditions
psoriasisplaque psoriasis
Beyond the preview
Go deeper on ChiCTR2600123675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123675.